The purpose of this program is to provide participants an early access to erdafitinib prior to market authorization (that is, Food and Drug Administration [FDA] approval in the United States). The program is limited to participants with advanced cancers and fibroblast growth factor receptor (FGFR) genetic alterations who have exhausted at least 2 lines of standard of care therapy and who are not eligible for an erdafitinib clinical trial.

Inclusion Criteria:

• Participant has a documented fibroblast growth factor receptor (FGFR) alteration
• Participant does not have co-morbidities that would alter risk-benefit of providing erdafitinib (determined by treating physician's assessment)
• Life expectancy is greater than (>) 3 months (determined by treating physician's assessment)
• Participant has exhausted treatment options for their disease (review of prior treatments)
• Participant is not eligible for other erdafitinib clinical trials including but not limited to BLC3001/NCT03390504 and BLC2002/NCT03473743